A life sciences company spends years being measured on something no ledger was designed to report: how long the money lasts, and what it bought. Biotech accounting software has to answer both, for a board, for a grantor and eventually for an auditor, while the underlying business changes shape every eighteen months.
That is the real difficulty. A two-person company with a molecule, a Series B company running three clinical programs, and a company with a commercial product and inventory are three different accounting problems wearing the same name. The finance system usually gets chosen at one stage and has to survive the next two.
What follows is what implementing that system actually involves. Which structures have to exist before the first transaction posts, where the board reporting breaks, what audit readiness requires in practice, and what changes for a small finance team after go-live.
Key Takeaways
- Program and funding source have to be part of the transaction structure from day one. Neither can be reconstructed retroactively across historical spend.
- Burn rate reporting a board will trust depends on accrual discipline, not on a dashboard. Uninvoiced CRO and contractor work is where the number goes wrong.
- Grant and restricted fund reporting is a design decision made before migration, because grantors ask for a cut of the data your old system may never have captured.
- Audit readiness is mostly about evidence being attached to transactions as they happen, not about assembling it in the weeks before fieldwork.
- Decide with your quality organization whether the finance system is in scope for validation. The answer changes documentation, not features.
- Choose a structure that survives the next stage. Adding a commercial product to a system designed only for research spend is a much larger change than it appears.
Screenshots throughout are Sage Intacct product material. The figures shown in them are Sage’s demonstration data, not Lucentive client results.
What makes biotech accounting software different
Life science accounting software has to report by program and funding source as fluently as it reports by account. The board wants burn and runway by program. The grantor wants spend against an award with its own period and rules. The auditor wants a trail. All three views come from the same transactions, tagged differently.
General accounting packages handle the third requirement well and the first two by export. That is manageable for a while. It stops being manageable at the point where a program manager needs to see committed spend against their own budget, or where a grant report has to reconcile exactly to the general ledger rather than approximately.
The stage-of-growth problem sits underneath all of it. Pre-clinical, the questions are about burn and program cost. In clinical, contract research organizations, site payments and accruals dominate. At commercial launch, inventory, revenue recognition and distributor arrangements arrive at once. A structure that answers only today’s questions will be rebuilt, and rebuilding a chart of accounts mid-trial is a bad quarter.
Grants, funding sources and program spending
The structural decision in life sciences accounting is that program, grant and funding source are dimensions on the transaction rather than segments buried in the account code. Tag spend as it posts and any view becomes available later. Leave it untagged and no amount of reporting effort recovers it.
This is the point that most affects a migration. Grantors and boards routinely ask for cuts of the data that the previous system never captured, such as spend by program by cost category by period, or personnel effort allocated across two awards. If those attributes were not recorded on the original transactions, they cannot be added afterwards without a manual allocation exercise that the auditor will then want to see documented.
So the design work happens before data migration. List the reports your funders and board actually require, work backwards to the tags those reports need, and decide which are mandatory on which transaction types. A funding source that is required on payables but optional on journal entries produces grant reports that do not tie to the ledger, which is the specific failure that costs credibility with a grantor. The mechanics of that design are covered in how dimensions reshape a chart of accounts.
Burn rate and program cost visibility
Program managers need to see committed and incurred cost against their own budget without waiting for a close, and the board needs a burn figure that does not move after the fact. Both depend on the same thing: costs recognized when they are incurred rather than when the invoice happens to arrive.
This is where board reporting most often goes wrong, and it is rarely a software failure. A contract research organization runs a month of work and invoices six weeks later. A consultant delivers in March and bills in May. If those costs land in the period the invoice arrived, burn looks flat and then spikes, runway calculations move, and the finance team spends the board meeting explaining a number rather than the business.
The fix is procedural and belongs in the implementation, not after it. Build the accrual process into the month-end checklist, give program managers a way to flag work performed but not yet billed, and put purchase commitments in front of them so committed spend is visible alongside incurred spend. Governance over that process is the same discipline described in ERP program management, applied to research programs rather than to the implementation itself.
[DATA: Lucentive’s typical timeline from kickoff to a first board-ready burn and runway report — Rich to confirm]
Automating approvals and paperless workflow
Automated workflow in Sage Intacct routes transactions for approval, records digital signoffs against the transaction, and removes the duplicate data entry that comes from re-keying between systems. For a small finance team supporting a much larger scientific organization, that is usually the most immediate return.
The design principle is that approvals should reflect who actually has authority over the spend, which in a research organization is often a principal investigator or program lead rather than a finance manager. Routing every purchase to the controller creates a queue in the one place with the least capacity. Routing it to the budget owner gets the coding right at source, because they know which program it belongs to.
The second principle is to attach evidence at the point of approval. The purchase order, the CRO contract, the statement of work, the receipt. This is the single cheapest thing a life sciences company can do for its future audit, and it costs almost nothing at the moment of entry.
Audit readiness: SOX, ASC 606 and revenue recognition
Audit readiness comes from transactions that carry their own evidence and an unbroken system-generated trail of who did what. Sage Intacct supports that through automated audit trails, configurable approval controls and revenue recognition handling aligned to ASC 606 and IFRS 15, which matters well before a company has revenue.
Pre-revenue companies often defer this thinking, and it is a mistake worth naming. Collaboration agreements, milestone payments, upfront fees and grant income all raise recognition questions that arrive before product revenue does. Setting the structure up while the transaction volume is low is far cheaper than restating once it is not. The detailed mechanics of multi-element and milestone recognition are covered in revenue recognition under ASC 606, and the principles carry over.
One implementation question deserves an early answer because it changes documentation rather than configuration. Ask your quality organization whether they consider the finance system in scope for computer system validation. Most treat the financial ledger as outside GxP scope, but the assumption should be confirmed rather than inherited, because if it is in scope the project needs validation documentation planned from the start rather than assembled afterwards.
The other half of audit readiness is data quality. An audit trail proves what was recorded; it does not prove the record was right. Building basic quality checks into the close, such as unallocated spend, transactions missing a program tag, and accruals with no supporting document, is what keeps the trail meaningful. That approach is set out in gaining confidence in decisions through data quality assurance.
Integrating across the technology stack
Sage Intacct connects to surrounding systems through an open API and prebuilt connectors, so payroll, expense management, procurement, clinical trial management and inventory systems can feed the ledger rather than being reconciled to it. The goal is that the finance system stops being a place where other systems’ data gets retyped.
Two integrations matter most, and they arrive at different stages. Payroll and expense come first, because personnel cost is the largest line in most research organizations and allocating effort across programs by hand does not scale. Clinical trial and site payment systems come next, because that volume grows quickly and manual handling is where accrual errors originate.
In every case the same question decides whether it works: which system owns the record, and who is notified when a sync fails. A silent integration failure is indistinguishable from a quiet month, and in a company reporting burn to investors, that distinction matters.
Sequencing the implementation as the company changes stage
A workable order: chart of accounts and dimensions first, then approval workflows, then payroll and expense integration, then accrual and close process, then grant and program reporting, then revenue recognition. Reporting comes late because it inherits every earlier decision, and revenue recognition is scoped early even when it will not be used yet.
Scoping ahead is the specific advice for this sector. A structure designed only for research spend has to be extended when a commercial product arrives, bringing inventory, cost of goods, distributor arrangements and a different revenue pattern. Deciding at design time that those dimensions and account groups will exist, even unused, is a small effort now and a large saving later.
[DATA: The number of entities a Lucentive life sciences client consolidates and how long that close now takes — Rich to confirm]
After go-live, a small finance team stops being the reporting function. A program manager opens their own cost view. A grant report runs rather than being assembled. The controller reviews exceptions: untagged spend, accruals without documents, programs trending past budget. The new responsibility is ownership of the program and funding source lists, worth assigning explicitly, because in a company adding programs and awards continuously an unowned value list gets messy fast.
Summary
Biotech and pharmaceutical accounting software earns its place by making program spend, burn and grant reporting come out of the ledger instead of a spreadsheet next to it. That requires program and funding source captured on transactions from the start, accrual discipline that makes burn stable, evidence attached at approval, and a structure scoped for the stage after the one you are in.
None of that is a feature you switch on. It is a set of decisions made before configuration, and they are the difference between a system that survives your next financing round and one that gets rebuilt during it.
The page this replaces offered an infographic behind a form. An infographic is fine for a business case and no use at all for deciding whether your program structure will hold through a clinical readout. Talk to Lucentive and bring your current chart of accounts, your grant reporting requirements and your board pack. Our consultants have 25+ years each in mid-market finance systems, and that is a more useful hour than any download.
Frequently asked questions
What should biotech accounting software do that general accounting software does not?
It has to report by program and funding source as naturally as by account, support accruals for contracted research work that is performed long before it is invoiced, and hold evidence against transactions for audit. General packages produce accurate financial statements and leave program and grant reporting to a spreadsheet, which works until a grantor asks for figures that must tie exactly to the ledger.
How does life science accounting software handle grants and restricted funding?
Funding source becomes a dimension on the transaction, so spend against an award can be reported for the award’s own period and rules while still rolling into the statutory accounts. The important constraint is timing: those tags have to exist when the transaction posts. Historical spend cannot be retroactively attributed to an award without a manual allocation exercise your auditor will want documented.
Does a pre-revenue biotech need to think about ASC 606?
Usually yes, earlier than expected. Collaboration agreements, upfront payments, milestone payments and some grant income raise recognition questions before there is any product revenue. Establishing the structure while transaction volume is low is much cheaper than restating later, and investors and auditors both look for it during diligence ahead of a financing round or an initial public offering.
What does audit readiness actually require day to day?
Mostly that evidence is attached to transactions as they are approved rather than gathered before fieldwork: purchase orders, contracts, statements of work, receipts. Beyond that it requires a system-generated trail of approvals and edits, and routine quality checks in the close for untagged spend and accruals without support. The work is small at entry and large if deferred.
How does pharmaceutical accounting software handle inventory and commercial launch?
Commercial launch adds inventory valuation, cost of goods sold, distributor and chargeback arrangements, and a revenue pattern that did not exist during research. The practical advice is to scope those structures at design time even if they will sit unused for two years, because extending a research-only chart of accounts and dimension set during a launch is a far more disruptive project than including them from the start.